Shots:

• Takeda to receive ~$660M for divesting its 20 select prescription pharmaceutical and OTC products traded in Russia- Georgia- and several countries within the Commonwealth of Independent States. STADA to get rights- title- and interest to the products in the portfolio exclusive in these countries. The transaction is expected to close in Q4’19
• Additionally- Takeda and STADA will sign manufacturing and supply agreement under which Takeda will continue to manufacture the products on behalf of STADA
• The divestiture allows Takeda to focus on its five key business areas- accelerating its deleveraging following its acquisition of Shire. The portfolio to be divested includes OTC vitamins and food supplement and select products within CV- diabetes- general medicine- and respiratory therapeutic areas

Click here to­ read full press release/ article 

 Ref: Takeda | Image: Takeda